Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IMAX Stock Forecast 2026-2027
$37.10
Current Price
$1.89B
Market Cap
Buy 10
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to IMAX Price Targets
+29.4%
To High Target of $48.00
+24.0%
To Median Target of $46.00
+10.5%
To Low Target of $41.00
IMAX Price Momentum
-2.0%
1 Week Change
-5.0%
1 Month Change
+65.3%
1 Year Change
+0.4%
Year-to-Date Change
-14.0%
From 52W High of $43.16
+72.6%
From 52W Low of $21.49
📊 TOP ANALYST CALLS
Did IMAX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if IMAX is one of their latest high-conviction picks.
Latest IMAX Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, IMAX has a bullish consensus with a median price target of $46.00 (ranging from $41.00 to $48.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $37.10, the median forecast implies a 24.0% upside. This outlook is supported by 10 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from David Karnovsky at JP Morgan, projecting a 29.4% upside. Conversely, the most conservative target is provided by Mike Burton at Goldman Sachs, suggesting a 10.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IMAX Analyst Ratings
10
Buy
1
Hold
0
Sell
IMAX Price Target Range
Low
$41.00
Average
$46.00
High
$48.00
Current: $37.10
Latest IMAX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IMAX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 8, 2026 | Seaport Global | David Joyce | Buy | Maintains | $45.00 |
| Mar 2, 2026 | Goldman Sachs | Mike Burton | Neutral | Maintains | $41.00 |
| Feb 26, 2026 | Benchmark | Mike Hickey | Buy | Maintains | $44.00 |
| Feb 26, 2026 | JP Morgan | David Karnovsky | Overweight | Maintains | $48.00 |
| Feb 26, 2026 | Macquarie | Chad Beynon | Outperform | Maintains | $45.00 |
| Feb 26, 2026 | Rosenblatt | Steve Frankel | Buy | Maintains | $47.00 |
| Feb 24, 2026 | Rosenblatt | Steve Frankel | Buy | Maintains | $47.00 |
| Feb 23, 2026 | Wedbush | Alicia Reese | Outperform | Reiterates | $46.00 |
| Jan 26, 2026 | Barrington Research | Patrick Sholl | Outperform | Maintains | $42.00 |
| Jan 15, 2026 | Macquarie | Chad Beynon | Outperform | Maintains | $44.00 |
| Dec 18, 2025 | Wells Fargo | Omar Mejias | Overweight | Maintains | $47.00 |
| Dec 15, 2025 | JP Morgan | David Karnovsky | Overweight | Upgrade | $47.00 |
| Dec 8, 2025 | Rosenblatt | Steve Frankel | Buy | Maintains | $47.00 |
| Dec 8, 2025 | Barrington Research | Patrick Sholl | Outperform | Maintains | $42.00 |
| Dec 8, 2025 | Wedbush | Alicia Reese | Outperform | Maintains | $46.00 |
| Dec 8, 2025 | Benchmark | Mike Hickey | Buy | Maintains | $42.00 |
| Nov 25, 2025 | Goldman Sachs | Mike Burton | Neutral | Upgrade | $34.00 |
| Oct 24, 2025 | Wells Fargo | Omar Mejias | Overweight | Maintains | $40.00 |
| Oct 24, 2025 | Rosenblatt | Steve Frankel | Buy | Maintains | $42.00 |
| Oct 24, 2025 | JP Morgan | David Karnovsky | Neutral | Maintains | $32.00 |
Imax Corporation (IMAX) Competitors
The following stocks are similar to IMAX based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Imax Corporation (IMAX) Financial Data
Imax Corporation has a market capitalization of $1.89B with a P/E ratio of 58.8x. The company generates $410.21M in trailing twelve-month revenue with a 8.5% profit margin.
Revenue growth is +35.1% quarter-over-quarter, while maintaining an operating margin of +26.6% and return on equity of +11.3%.
Valuation Metrics
Market Cap
$1.89B
Enterprise Value
$2.22B
P/E Ratio
58.8x
PEG Ratio
-0.7x
Price/Sales
4.9x
Growth & Margins
Revenue Growth (YoY)
+35.1%
Gross Margin
+57.6%
Operating Margin
+26.6%
Net Margin
+8.5%
EPS Growth
-88.0%
Financial Health
Cash/Price Ratio
+7.5%
Current Ratio
4.4x
Debt/Equity
67.7x
ROE
+11.3%
ROA
+6.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Imax Corporation (IMAX) Business Model
About Imax Corporation
What They Do
Designs and produces immersive theater systems.
Business Model
Imax Corporation generates revenue by partnering with major film studios to create IMAX-formatted versions of films, enhancing the viewing experience with superior technology. Additionally, the company operates its own theaters and collaborates with multiplexes, allowing it to monetize both film presentations and ticket sales on a global scale.
Additional Information
Imax is recognized for its high standards in the film exhibition industry and continually innovates in laser projection and audio technology, positioning itself as a leader in transforming moviegoing experiences in both 2D and 3D formats.
Company Information
Sector
Communication Services
Industry
Entertainment
Employees
700
CEO
Mr. Richard Lewis Gelfond J.D.
Country
Canada
IPO Year
1994
Website
www.imax.comImax Corporation (IMAX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Imax (IMAX) Earnings Expected to Grow: Should You Buy?
Imax (IMAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apr 15, 2026
By Zacks Equity Research
Tale of the Tape
Here's Why Imax (IMAX) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Apr 09, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Gelfond sold 135,046 shares for ~$5.11 million at ~$37.82 per share on April 10, 2026, reducing his holdings to 1,530,004 shares, an 8.11% decrease.
Why It Matters
Gelfond's sale of 8.11% of his shares may signal potential concerns about the company's outlook, impacting investor confidence and potentially the stock price.
Source: The Motley Fool
Market Sentiment:
Negative
Quick Summary
Imax (IMAX) is unlikely to meet earnings expectations in its upcoming report due to lacking key performance indicators. Investors should prepare for potentially disappointing results.
Why It Matters
Imax's anticipated earnings report may disappoint, indicating potential revenue challenges, which could negatively impact stock performance and investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Zacks Style Scores can assist investors in selecting strong stocks that may outperform the market for their investment portfolios.
Why It Matters
The Zacks Style Scores can help identify high-potential stocks, aiding investors in making informed decisions for better portfolio performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Zacks Style Scores can help investors identify strong stocks that may outperform the market for their investment portfolios.
Why It Matters
The Zacks Style Scores can help identify high-potential stocks, guiding investors toward selections that may outperform the market, enhancing portfolio performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
IMAX says CEO taking medical leave
18 days ago
Quick Summary
IMAX CEO Richard Gelfond is on temporary medical leave due to pneumonia, as announced on Monday.
Why It Matters
CEO Richard Gelfond's medical leave may raise concerns about IMAX's leadership stability and operational continuity, potentially affecting investor confidence and stock performance.
Source: Reuters
Market Sentiment:
Negative
Quick Summary
Imax CEO Rich Gelfond is on temporary medical leave due to pneumonia. The company stated he is receiving excellent care and is progressing in his recovery.
Why It Matters
Leadership changes can impact company strategy and performance. Gelfond's absence may create uncertainty around Imax's direction and investor sentiment, affecting stock performance.
Source: Deadline
Market Sentiment:
Neutral
Frequently Asked Questions About IMAX Stock
What is Imax Corporation's (IMAX) stock forecast for 2026?
Based on our analysis of 19 Wall Street analysts, Imax Corporation (IMAX) has a median price target of $46.00. The highest price target is $48.00 and the lowest is $41.00.
Is IMAX stock a good investment in 2026?
According to current analyst ratings, IMAX has 10 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $37.10. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IMAX stock?
Wall Street analysts predict IMAX stock could reach $46.00 in the next 12 months. This represents a 24.0% increase from the current price of $37.10. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Imax Corporation's business model?
Imax Corporation generates revenue by partnering with major film studios to create IMAX-formatted versions of films, enhancing the viewing experience with superior technology. Additionally, the company operates its own theaters and collaborates with multiplexes, allowing it to monetize both film presentations and ticket sales on a global scale.
What is the highest forecasted price for IMAX Imax Corporation?
The highest price target for IMAX is $48.00 from David Karnovsky at JP Morgan, which represents a 29.4% increase from the current price of $37.10.
What is the lowest forecasted price for IMAX Imax Corporation?
The lowest price target for IMAX is $41.00 from Mike Burton at Goldman Sachs, which represents a 10.5% increase from the current price of $37.10.
What is the overall IMAX consensus from analysts for Imax Corporation?
The overall analyst consensus for IMAX is bullish. Out of 19 Wall Street analysts, 10 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $46.00.
How accurate are IMAX stock price projections?
Stock price projections, including those for Imax Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 17, 2026 9:00 PM UTC